Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#191 / 200 Total
KRRO - Korro Bio Inc - Stock Price Chart
TickerKRRO [NASD, RUT]
CompanyKorro Bio Inc
CountryUSA
IndustryBiotechnology
Market Cap138.22MEPS (ttm)-9.44
P/E-EPS this Y-0.98%
Forward P/E-EPS next Y5.99%
PEG-EPS past 5Y21.83%
P/S28.68EPS next 5Y-0.48%
P/B0.99EPS Q/Q-2.20%
Dividend-Sales Q/Q-
Insider Own41.54%Inst Own70.42%
Insider Trans0.00%Inst Trans5.05%
Short Float16.86%EarningsMay 07/a
Analyst Recom1.00Target Price94.11
Avg Volume133.85K52W Range10.29 - 98.00
Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company was founded by Nessan Bermingham, Jean-Francois B. Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Agarwal VineetChief Financial OfficerNov 11 '24Option Exercise11.688009,344800Nov 12 07:40 PM
Agarwal VineetChief Financial OfficerNov 11 '24Sale70.0080056,0000Nov 12 07:40 PM
Agarwal VineetOfficerNov 11 '24Proposed Sale70.0080056,000Nov 12 08:28 AM
Agarwal VineetChief Financial OfficerOct 17 '24Option Exercise11.9910,216122,46810,216Oct 18 07:43 PM
Agarwal VineetChief Financial OfficerOct 17 '24Sale78.2610,216799,5270Oct 18 07:43 PM
ELUT - Elutia Inc - Stock Price Chart
TickerELUT [NASD]
CompanyElutia Inc
CountryUSA
IndustryMedical Devices
Market Cap101.14MEPS (ttm)-1.94
P/E-EPS this Y65.59%
Forward P/E-EPS next Y32.81%
PEG-EPS past 5Y-10.72%
P/S4.27EPS next 5Y-
P/B-EPS Q/Q71.72%
Dividend-Sales Q/Q-9.92%
Insider Own39.03%Inst Own39.35%
Insider Trans5.52%Inst Trans281.50%
Short Float0.14%EarningsMay 08/a
Analyst Recom1.00Target Price7.50
Avg Volume33.33K52W Range1.61 - 5.12
Elutia, Inc. is a biotechnology company, which engages in the provision of biologic products to improve compatibility between medical devices and the patients who need them. It operates through the following segments: Device Protection, Women's Health, and Cardiovascular. The Device Protection segment includes biological envelope that remodels into systematically connected, vascularized tissue for the long-term pocket protection of certain cardiac and neurostimulator implantable electronic vehicles. The Women's Health segment includes pre-hydrated, human acellular dermal matrix, or HADM, that is designed to enable rapid integration, cellular repopulation and rapid revascularization at the surgical site. The Cardiovascular segment includes a variety of viable matrices, produced with a proprietary process that is designed to protect and preserve native bone cells and reduce programmable cell death, for use in bone repair and fusion procedures. The Cardiovascular segment includes a portfolio of extracellular matrices that retain the natural composition of collagen, growth factors and proteins for use in vascular and cardiac repair and pericardial closure. The company was founded by Kevin L. Rakin and Charles Randal Mills on August 6, 2015 and is headquartered in Gaithersburg, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HighCape Capital, L.P.DirectorFeb 03 '25Buy2.50420,0001,050,0009,520,232Mar 13 04:30 PM
HighCape Capital, L.P.DirectorFeb 03 '25Buy2.50420,0001,050,0009,520,232Mar 13 04:28 PM
Ferguson MatthewCHIEF FINANCIAL OFFICERJul 31 '24Option Exercise1.43105,080150,002257,823Jul 31 05:00 PM
ELVN - Enliven Therapeutics Inc - Stock Price Chart
TickerELVN [NASD, RUT]
CompanyEnliven Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap1.27BEPS (ttm)-1.93
P/E-EPS this Y-10.22%
Forward P/E-EPS next Y-17.12%
PEG-EPS past 5Y19.02%
P/S-EPS next 5Y-20.26%
P/B3.67EPS Q/Q-5.45%
Dividend-Sales Q/Q-
Insider Own34.27%Inst Own61.32%
Insider Trans-0.91%Inst Trans0.90%
Short Float17.07%EarningsMay 14/a
Analyst Recom1.10Target Price40.44
Avg Volume477.20K52W Range13.30 - 30.03
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Patel AnishOfficerJul 07 '25Proposed Sale20.736,667138,207Jul 07 04:15 PM
Hohl BenjaminCHIEF FINANCIAL OFFICERJun 27 '25Option Exercise2.483,2508,06026,250Jul 01 04:42 PM
Hohl BenjaminCHIEF FINANCIAL OFFICERJun 27 '25Sale20.913,25067,95623,000Jul 01 04:42 PM
Hohl BenjaminOfficerJun 27 '25Proposed Sale21.524,25091,460Jun 27 04:01 PM
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICERJun 20 '25Sale21.4012,500267,458965,188Jun 24 05:36 PM
BAK - Braskem S.A. ADR - Stock Price Chart
TickerBAK [NYSE]
CompanyBraskem S.A. ADR
CountryBrazil
IndustryChemicals
Market Cap633.19MEPS (ttm)-4.19
P/E-EPS this Y88.84%
Forward P/E-EPS next Y57.86%
PEG-EPS past 5Y-24.21%
P/S0.04EPS next 5Y-
P/B-EPS Q/Q143.93%
Dividend-Sales Q/Q-8.05%
Insider Own-Inst Own4.81%
Insider Trans-Inst Trans-
Short Float1.71%EarningsMay 09/b
Analyst Recom2.64Target Price5.48
Avg Volume880.82K52W Range2.85 - 7.71
Braskem SA engages in the manufacture of petrochemicals and other related products. It operates through the following segments: Brazil, USA, and Europe and Mexico. The Brazil segment includes production and sale of chemicals, supply of electricity, and production and sale of PE. The USA and Europe segment involves production, operation, and sale of polypropylene in the United States and Germany. The Mexico segment comprises production, operation, and sale of ethylene, high-density polyethylene and low-density polyethylene in Mexico. The company was founded in August 2002 and is headquartered in Butanta, Brazil.
MCTR - CTRL Group Ltd - Stock Price Chart
TickerMCTR [NASD]
CompanyCTRL Group Ltd
CountryHong Kong
IndustryAdvertising Agencies
Market Cap50.18MEPS (ttm)0.00
P/E1426.09EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S11.33EPS next 5Y-
P/B93.93EPS Q/Q-63.76%
Dividend-Sales Q/Q-25.37%
Insider Own-Inst Own0.00%
Insider Trans-Inst Trans0.00%
Short Float-Earnings-
Analyst Recom-Target Price-
Avg Volume1.61M52W Range2.48 - 54.91
Ctrl Group Ltd. is a holding company, which engages in the provision of marketing and advertising services. It offers one-stop advertising services to clients throughout the entire advertising process, which comprises the planning, creating, launching, managing, and performance monitoring of the advertisements. The company was founded by Kai Kwan Lam, Chi Fung Lau, and Chun Pong Siu on May 13, 2022 and is headquartered in Hong Kong.
UNCY - Unicycive Therapeutics Inc - Stock Price Chart
TickerUNCY [NASD]
CompanyUnicycive Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap68.70MEPS (ttm)-2.05
P/E-EPS this Y69.51%
Forward P/E0.33EPS next Y1044.64%
PEG-EPS past 5Y-31.80%
P/S-EPS next 5Y-
P/B5.72EPS Q/Q91.72%
Dividend-Sales Q/Q-
Insider Own17.08%Inst Own47.93%
Insider Trans0.00%Inst Trans-
Short Float3.49%EarningsMay 14/b
Analyst Recom1.00Target Price62.76
Avg Volume582.31K52W Range2.02 - 11.00
Jul-08-25 08:30AM Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) +5.97%
Jul-07-25 07:00AM Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference (GlobeNewswire)
Jun-30-25 07:05AM Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis (GlobeNewswire) -29.85%
Jun-17-25 07:00AM Unicycive Therapeutics, Inc. Announces Reverse Stock Split (GlobeNewswire) -8.96%
Jun-10-25 06:00AM Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis (GlobeNewswire) -40.88%
May-22-25 07:00AM Unicycive Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-21-25 07:00AM Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders (GlobeNewswire) -5.00%
May-14-25 07:15AM Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -7.83%
Apr-10-25 08:00AM Unicycive Presents New Patient-Level Data Underscoring Challenges Faced with Current Phosphate Binders and Highlighting the Potential of Oxylanthanum Carbonate to Address Barriers to Adherence for Patients with Hyperphosphatemia on Dialysis (GlobeNewswire)
Apr-01-25 07:00AM Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire) -5.03%
Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.
TCRX - Tscan Therapeutics Inc - Stock Price Chart
TickerTCRX [NASD]
CompanyTscan Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap104.12MEPS (ttm)-1.09
P/E-EPS this Y-10.90%
Forward P/E-EPS next Y6.55%
PEG-EPS past 5Y-14.41%
P/S23.56EPS next 5Y9.18%
P/B0.50EPS Q/Q17.15%
Dividend-Sales Q/Q283.57%
Insider Own22.56%Inst Own71.35%
Insider Trans25.43%Inst Trans6.83%
Short Float5.17%EarningsMay 06/b
Analyst Recom1.14Target Price8.50
Avg Volume629.61K52W Range1.02 - 7.89
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lynx1 Capital Management LP10% OwnerMay 19 '25Buy1.201,388,7941,666,5536,746,141May 21 04:49 PM
Lynx1 Capital Management LP10% OwnerMay 20 '25Buy1.201,200,0001,440,0007,946,141May 21 04:49 PM
Lynx1 Capital Management LP10% OwnerDec 13 '24Buy2.90100,000290,1405,357,347Dec 16 04:26 PM
Lynx1 Capital Management LP10% OwnerDec 12 '24Buy3.0131,80095,6295,257,347Dec 16 04:26 PM
Lynx1 Capital Management LP10% OwnerNov 15 '24Buy4.349474,1145,225,547Nov 19 04:26 PM
EWTX - Edgewise Therapeutics Inc - Stock Price Chart
TickerEWTX [NASD, RUT]
CompanyEdgewise Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap1.48BEPS (ttm)-1.55
P/E-EPS this Y-20.45%
Forward P/E-EPS next Y-15.37%
PEG-EPS past 5Y-49.00%
P/S-EPS next 5Y-10.76%
P/B3.12EPS Q/Q-31.65%
Dividend-Sales Q/Q-
Insider Own26.72%Inst Own74.46%
Insider Trans3.40%Inst Trans11.28%
Short Float16.26%EarningsMay 08/b
Analyst Recom1.36Target Price38.45
Avg Volume1.08M52W Range10.60 - 38.12
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Russell Alan JChief Scientific OfficerMay 01 '25Option Exercise0.005,209020,072May 07 09:10 PM
Russell Alan JChief Scientific OfficerMay 02 '25Sale16.451,55125,52018,521May 07 09:10 PM
MOORE JOHN RGeneral CounselMay 01 '25Option Exercise0.005,20908,461May 07 09:10 PM
MOORE JOHN RGeneral CounselMay 02 '25Sale16.451,93031,7576,531May 07 09:10 PM
KOCH KEVINPresident and CEOMay 01 '25Option Exercise0.0010,417024,895May 07 09:10 PM
INO - Inovio Pharmaceuticals Inc - Stock Price Chart
TickerINO [NASD]
CompanyInovio Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap73.90MEPS (ttm)-3.19
P/E-EPS this Y48.65%
Forward P/E-EPS next Y12.08%
PEG-EPS past 5Y22.92%
P/S263.91EPS next 5Y39.23%
P/B1.04EPS Q/Q61.02%
Dividend-Sales Q/Q-
Insider Own0.79%Inst Own37.09%
Insider Trans0.00%Inst Trans1.80%
Short Float-EarningsMay 13/a
Analyst Recom1.67Target Price7.50
Avg Volume1.21M52W Range1.30 - 12.33
TodayInitiated Piper Sandler Overweight $5
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
PUBM - PubMatic Inc - Stock Price Chart
TickerPUBM [NASD, RUT]
CompanyPubMatic Inc
CountryUSA
IndustrySoftware - Application
Market Cap659.09MEPS (ttm)0.08
P/E160.14EPS this Y-193.22%
Forward P/E680.02EPS next Y109.32%
PEG13.88EPS past 5Y90.42%
P/S2.29EPS next 5Y11.54%
P/B2.38EPS Q/Q-300.41%
Dividend-Sales Q/Q-4.31%
Insider Own17.75%Inst Own54.44%
Insider Trans-4.64%Inst Trans-4.77%
Short Float4.82%EarningsMay 08/a
Analyst Recom1.91Target Price15.50
Avg Volume601.41K52W Range7.46 - 22.99
PubMatic, Inc. engages in the provision of specialized cloud infrastructure platform for advertising transactions. Its technology and infrastructure caters both Internet content creators and advertisers. It operates through the following geographical segments: United States, EMEA, APAC, and Rest of the World. The company was founded by Anand Das, Rajeev Kumar Goel, Amar Goel, and Mukul Kumar in 2006 and is headquartered in Redwood City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rajeev GoelOfficerJul 07 '25Proposed Sale12.4444,000547,360Jul 07 06:01 PM
Klimenko PaulinaCHIEF GROWTH OFFICERJul 01 '25Option Exercise0.0021,335059,927Jul 03 06:43 PM
Klimenko PaulinaCHIEF GROWTH OFFICERJul 02 '25Sale12.568,147102,35351,780Jul 03 06:43 PM
Kumar MukulPRESIDENT, ENGINEERINGJul 01 '25Option Exercise0.0013,861074,326Jul 03 06:42 PM
Kumar MukulPRESIDENT, ENGINEERINGJul 02 '25Sale12.565,36667,41568,960Jul 03 06:42 PM
110151617181920